New Plan To Double Drug Approvals Offers Few Fresh Ideas

Law360, New York (September 26, 2012, 7:23 PM EDT) -- A new presidential commission report falls short in calling on regulators to double the number of new drug approvals per year within the next decade, offering few new or creative ways to speed approvals or incentivize the right kind of innovation, experts say.

The report, released Tuesday, recommends that the U.S. Food and Drug Administration expand the accelerated approval pathway to new drugs, find ways to make clinical trials smaller and cheaper, and study ways to offer incentives to drug companies to develop treatments that may...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.